Participated · Equity · Nov 2021

Illumigyn developed the Gynescope System, an FDA-cleared remote gynecological imaging platform that digitally documents the cervix, vagina and external genitalia. The HIPAA-compliant system automatically uploads and securely stores high-resolution images to the cloud, enabling remote specialist review and giving women access to their scans and doctors’ recommendations. Illumigyn says its high-resolution magnification can produce more accurate smear tests than traditional exams and is designed to be handled by trained caregivers such as OB/GYNs, general practitioners, nurse practitioners and physician assistants. The company announced it closed $33 million in funding from investors including Yozma Group Korea and Ubicom Holdings Japan, with other investors not disclosed. Proceeds will be used to ramp up production, support research and development toward a comprehensive lower genital tract examination solution, and to execute distribution agreements and new global partnerships. Illumigyn said it is expanding into the United States, United Arab Emirates, India, Singapore and South Korea starting this month and is targeting women worldwide aged 15 and older.

Led · Series B · May 2021

UltraSight, formerly OnSight Medical, is a Tel Aviv-based digital health company that develops an AI platform for ultrasound devices to perform real-time sonography at the point of care. Its core product provides real-time AI guidance for cardiac imaging across clinics, community hospitals, ambulances and remote settings. The company recently raised $13M in a Series B funding round. UltraSight intends to use the funds to advance U.S. clinical programs for its real-time AI guidance in a variety of care settings. Led by CEO Davidi Vortman, UltraSight aims to enable medical professionals to diagnose patients wherever they are. The company focuses on point-of-care sonography to expand access to cardiac imaging.